Reading VIR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track VIR free→Reading VIR? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track VIR free→NASDAQHealth CareBiotechnologySnapshot 2026-06-16
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is neutral, and management's recent track record has been fairly steady. The company was unprofitable over the past year, so its earnings quality can't be assessed. Risk is elevated, and the sector backdrop is a headwind, which could impact future performance. If VIR cuts guidance on the next call, that would be a meaningful negative, as the Street tends to walk down estimates and the stock usually takes a leg lower. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 0 valuation methods, at three horizons. Current price $8.61. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
Not enough valuation methods to set a 12-month read yet.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
Not enough peers to compare yet.
Self-history needs ~20 months of data.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 3 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 0.51x of net income into operating cash flow.
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity.
7 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.90 → $0.90 (+0.0% / 30d). 0 raised, 0 cut, 5 covering analysts.
0 upgrades, 0 downgrades / 30d, 2 maintained. 100% of analysts rate Buy.
1 PT revisions / 30d. Avg target 227.3% above current price.
0 positive, 0 negative / 30d.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$258.
How much price usually moves either way.
On a bad day, this stock has moved -$561.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $2,782.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Earnings results will show if the company can keep growing after the recent earnings beat.
Confirms:Q2 earnings were better than expected. This shows that revenue is still growing.
Disproves:Q2 earnings were lower than expected. This suggests there may be revenue problems.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
Positive data enhances product potential and revenue outlook.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On June 9, 2026, the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company), upon the recommendation of the Nominating and Corporate Governance Committee of the Board, approved an increase in the size of the Board from seven to eight members and the appointment of Timothy Coughlin, CPA, to fill the newly created vacancy and serve o…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
No score history yet for this stock.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
A side-by-side read on sector standing, valuation, and risk versus Biotechnology.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
VIR Vir Biotechnology, Inc. | — | — | elevated |
ABBV AbbVie | Above typical Show detailsSector percentile: 86 of 100 | fair | low |
AMGN Amgen | Above typical Show detailsSector percentile: 81 of 100 | full | moderate |
GILD Gilead Sciences | Above typical Show detailsSector percentile: 99 of 100 | fair | moderate |
VRTX Vertex Pharmaceuticals | Above typical Show detailsSector percentile: 80 of 100 | expensive | moderate |
Not investment advice. As of 2026-06-16.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Vir aims to extend its cash runway into the second half of 2028 through disciplined resource deployment.
Vir is committed to maintaining disciplined resource deployment to support its financial strategy.
Why it matters: Extending cash runway is key for funding trials and operations. It shows financial health and stability.
Confirms:The company has enough cash and investments to run operations until late 2028.
Disproves:Company says cash runway is shorter than expected and needs more financing.
Why it matters: A drop in revenue growth could signal a shift in the health care sector's growth phase.
Confirms:Revenue growth falls below the sector median growth rate.
Disproves:Revenue growth stays above the sector median growth rate.
Why it matters: Good results could support the partnership with Astellas and help future development. This is important for prostate cancer treatment.
Confirms:New Phase 1 data shows good anti-tumor effects and safety.
Disproves:New data shows no good anti-tumor effects or safety problems.
Why it matters: Leadership changes can change company plans. They can also affect how investors feel.
Confirms one read:New director brings a strong background and positive changes to governance.
Confirms the other:A transition can cause instability. It may also lead to bad changes in management.
Why it matters: Earnings results will show if the company can extend its cash runway into 2028.
Confirms one read:Earnings report shows a cash balance that extends runway into 2028.
Confirms the other:The earnings report shows a cash balance that means less time to operate.
Why it matters: This data could show if the treatment for chronic hepatitis delta works. Good results would help change care standards.
Confirms:Complete Week 96 data shows at least 88% of participants had undetectable HDV RNA.
Disproves:Data shows less than 88% of participants had undetectable HDV RNA.
Partnership and clinical progress support growth strategy.
Valuation insights align with revenue opportunity narrative.
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On May 25, 2026, Saira Ramasastry, M.S., M.Phil., a member of the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company) and Chair of the Company’s Audit Committee (the Audit Committee), informed the Company that, due to a business conflict, she will be stepping down from her role as a member of the Board and the Audit Committee, e…
Results of Operations and Financial Condition. On May 6, 2026, Vir Biotechnology, Inc. (the Company) issued a press release announcing its financial results for the quarter ended March 31, 2026. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated herein by reference. The information in this Item 2.02, including the attached Exhibit 99.1, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, a…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On April 7, 2026, Mark Eisner, MD, MPH, Executive Vice President and Chief Medical Officer of Vir Biotechnology, Inc. (the Company), informed the Company that he will be stepping down from his role, effective April 24, 2026. The Company has initiated a search for his successor. SIGNATURES Pursuant to the requirements of the Securities Exchange Act…
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 4, 2026, the Board of Directors of Vir Biotechnology, Inc. (Vir Bio) appointed Marianne De Backer, M.Sc., Ph.D., MBA, Vir Bio’s Chief Executive Officer and principal executive officer, to the additional position of President. Biographical information regarding Dr. De Backer that is responsive to Items 401(b) and (e) of Regulation S-K is in…